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Platensimycin (PTM) and platencin (PTN) are potent
inhibitors of bacterial fatty acid synthases and have
emerged as promising antibacterial drug leads. We
previously characterized the PTM and PTN bio-
synthetic machineries in the Streptomyces platensis
producers. We now identify two mechanisms for
PTM and PTN resistance in the S. platensis pro-
ducers—the ptmP3 or ptnP3 gene within the PTM-
PTN or PTN biosynthetic cluster and the fabF gene
within the fatty acid synthase locus. PtmP3/PtnP3
and FabF confer PTM and PTN resistance by target
replacement and target modification, respectively.
PtmP3/PtnP3 also represents an unprecedented
mechanism for fatty acid biosynthesis in which
FabH and FabF are functionally replaced by a single
condensing enzyme. These findings challenge the
current paradigm for fatty acid biosynthesis and
should be considered in future development of effec-
tive therapeutics targeting fatty acid synthase.INTRODUCTION
The rapid development of antibiotics beginning more than 60
years ago was one of the most important advancements in the
history of treating human disease. Pathogenic bacteria, how-
ever, remain a threat to human health, and the inevitable
tendency of bacteria to evolve toward resistance to present ther-
apeutics is well recognized and cause for concern. The discov-
ery of platensimycin (PTM) and platencin (PTN), the second
entirely new class of natural antibiotics with a distinct mode of
action discovered in the past four decades, represents an
encouraging step toward addressing a pharmaceutical pipeline
that is inadequately producing a sufficient number of drugs to
treat newly emergent and resistant pathogenic strains (Taubes,
2008; Wang et al., 2006, 2007). It has been reported recentlyChemistry & Biology 21, 3that PTM is also a potent and selective inhibitor of mammalian
fatty acid synthase (Wu et al., 2011).
PTM and PTN act by inhibiting bacterial fatty acid synthase
(FASII; Figure 1). PTM selectively inhibits b-ketoacyl-acyl carrier
protein (ACP) synthases (KAS) I/II, or FabB/F, while PTN is a dual
inhibitor of both FabF and KAS III, or FabH (Wang et al., 2006,
2007). These FASII enzymes catalyze unique condensation
reactions, representing essential steps for chain initiation (by
FabH) and elongation (by FabB/F) in fatty acid biosynthesis (Fig-
ure 1B). Importantly, both PTM and PTN show broad spectrum
antibacterial activity, do not exhibit cross-resistance to clinically
relevant pathogens, and have shown in vivo efficacy without
toxicity (Wang et al., 2006, 2007). While poor pharmacokinetic
profiles have limited development of these compounds into
clinically significant therapeutics, synthetic strategies toward
PTM and PTN analogs and isolation of natural congeners from
native and engineered producing strains aim to overcome these
limitations (Martens and Demain, 2011; Saleem et al., 2011;
Shen et al., 2009; Smanski et al., 2012; Yu et al., 2010, 2013;
Zhang et al., 2011).
Among our studies on the biosynthetic gene clusters respon-
sible for PTM and PTN production in Streptomyces platensis
strains (Smanski et al., 2011), we sought to identify the self-resis-
tance mechanism(s) in these producing organisms. Character-
ization of the PTM and PTN biosynthetic machineries revealed
that S. platensis MA7327 is a PTM and PTN dual producer and
therefore must maintain resistance to both PTM and PTN.
S. platensis MA7339 is an exclusive PTN producer and must
minimally maintain resistance to PTN, but not necessarily to
PTM; however, the dual inhibitory nature of PTN suggests that
a resistance element for PTN could also confer resistance to
PTM. In addition, we previously introduced the ‘‘PTM cassette,’’
a 5.4-kb DNA fragment consisting of five genes present within
the PTM-PTN dual-producing cluster but absent within the
PTN cluster (Figure S1A available online) into the MA7339 strain.
This afforded a PTM and PTN dual-producing recombinant
strain, confirming that the MA7339 strain maintains resistance
to both PTN and PTM (Smanski et al., 2011). Bioinformatics anal-
ysis of the open reading frames within both the PTM-PTN dual-
producing cluster (S. platensis MA7327) and the PTN cluster89–397, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 389
Figure 1. PTM and PTN Structure and FAS Cycle
Structures of platensimycin and platencin (A) and the bacterial fatty acid synthase (FASII; B). Highlighted in red are (1) PTM inhibiting FabF/B, the elongation step
of FASII, and PTN dually inhibiting FabF and FabH, the initiation step FASII; and (2) the two complementarymechanisms of PTM andPTN resistance inS. platensis
by target replacement (i.e., FabF and FabH by PtmP3) and target modification (i.e., FabF by a PTM-insensitive variant). See also Figure S1.
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ptmP1/ptmP2/ptmP3/ptmP4 or ptnP1/ptnP2/ptnP3/ptnP4 in
the PTM-PTN and PTN clusters, respectively—without apparent
roles in biosynthesis or regulation, whichmight encode elements
conferring resistance to PTM, PTN, or both (Figure S1A and
Table S1; Smanski et al., 2011).
Development of resistance in pathogenic bacteria has widely
been attributed to horizontal gene transfer from nonpathogenic
bacteria with one potential source being antibiotic-producing
bacteria that developed highly effective mechanisms to avoid
suicide (D’Costa et al., 2006; Hopwood, 2007). This hypothesis
is supported by examples in vancomycin and aminoglycoside
clinical resistance mechanisms (Benveniste and Davies, 1973;
Marshall et al., 1997; Pootoolal et al., 2002). Understanding
self-resistance mechanisms within PTM- and PTN-producing
organisms therefore is imperative for predicting, determining,
and thereby managing, potential resistance that could develop
with any future use of PTM, PTN, or their derivatives in the
clinic.
Here we report identification of PtmP3/PtnP3 as the major
self-resistance conferring element in the native PTM-PTN dual
producerS. platensisMA7327 and the PTN producerS. platensis
MA7339. We demonstrate that PtmP3 can functionally replace
both the FabF and FabH enzymes of the housekeeping FASII
in Streptomyces species. Investigation of the FabF and FabH
enzymes within the FASII locus of the S. platensis strains further
reveals that FabF is also resistant to PTM, providing a second
form of self-resistance to PTM, while FabH remains sensitive
to PTN. PtmP3 and FabF in the PTM- and PTN-producing
S. platensis species therefore confer PTM and PTN resistance
by target replacement (i.e., FabF and FabH by PtmP3) and target390 Chemistry & Biology 21, 389–397, March 20, 2014 ª2014 Elseviemodification (i.e., FabF by a PTM-insensitive variant), respec-
tively (Figure 1B). PtmP3 represents an intriguing mechanism
for fatty acid biosynthesis in which FabH and FabF are function-
ally replaced by a single condensing enzyme. These findings
challenge the current paradigm for fatty acid biosynthesis and
should be considered in the future development of effective
therapeutics targeting FASII.
RESULTS
Bioinformatics Analysis Reveals Candidates for Self-
Resistance Genes
Four genes within the PTM and PTN biosynthetic clusters—
ptmP1/ptmP2/ptmP3/ptmP4 or ptnP1/ptnP2/ptnP3/ptnP4—
were previously ruled out as contributors to, or regulators of,
the biosynthetic reactions leading to production of PTM and
PTN (Smanski et al., 2011). Bioinformatics analysis assigned
these genes putative roles in self-resistance based on their
homology to enzymes of known functions (Figure S1A and Table
S1; Smanski et al., 2011). The N-terminal regions of PtmP1/
PtnP1 show sequence similarity to KAS III condensing enzymes;
however, while this region retains asparagine and histidine in a
conserved Cys-Asn-His catalytic triad, it lacks the cysteine res-
idue essential in forming the acyl-enzyme intermediate during
the condensation reaction (White et al., 2005). PtmP2/PtnP2
show sequence similarity to acetyl-CoA acetyltransferases,
which belong to the thiolase family of enzymes. Interestingly,
structural features, including an N-terminal region containing a
cysteine residue (Cys85) and a C-terminal region containing a
histidine residue (His338), align with conserved active site
regions in both thiolases and KAS condensing enzymes.r Ltd All rights reserved
Table 1. PTM and PTN Susceptibility of S. platensis and S. albus
J1074 Wild-Type and Recombinant Strains as Measured by
Minimum Inhibitory Concentration
Strain Name Genotype
MIC (mg/ml)
PTM PTN
S. platensis
MA7327 wild-type >256 >64
MA7339 wild-type >256 >64
SB12021 MA7327/DptmU4-P4 >256 32
S. albus
J1074 wild-type 64 0.125
SB12011 pBS12018 (ptmP3) >256 >64
SB12017 pBS12028 (ptmP3[C162L]) 64 <0.0625
SB12013 pBS12020 (S.p. fabF) >256 32
SB12014 pBS12021 (S.p. fabH) 32 <0.0625
SB12018 pBS12029 (S.a. fabF) 32 <0.0625
SB12019 pBS12030 (S.a. fabH) 128 0.125
MIC, minimum inhibitory concentration.
See also Figures S4 and S5.
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critical for either thiolase or condensing enzyme activity: a
C-terminal catalytic cysteine residue for type II thiolase activity
or a second C-terminal catalytic His/Asn residue for condensing
enzyme activity (Huang et al., 1998; Kursula et al., 2002).
PtmP3/PtnP3 are FabF (KAS II) homologs, retaining the three
key residues in a Cys-His-His catalytic triad conserved among
KAS I/II enzymes (Figure S2; White et al., 2005). The similarity
of PtmP1-P3/PtnP1-P3 to condensing enzymes, the targets
of PTM and PTN, led to their classification as putative resis-
tance elements. Finally, PtmP4/PtnP4 show high similarity to
members of the major facilitator superfamily, suggesting a role
in efflux activity and possible resistance (Kumar and Schweizer,
2005).
Streptomyces Species Are Sensitive to Both PTM and
PTN
To identify a suitable naive host for resistance studies, the sus-
ceptibility of various Streptomyces strains to PTM and PTN
was determined using a standard disk diffusion assay (see
Experimental Procedures). Clear zones of growth inhibition
were observed around discs impregnated with PTM or PTN on
R2YE agar plates inoculated with Streptomyces albus J1074
and Streptomyces avermitilis SUK-A4, whereas faint zones of in-
hibition were observed on plates inoculated with Streptomyces
lividans K4-114 and Streptomyces coelicolor CH999 (Figure S3).
S. albus J1074 was selected as a suitable naive host. Both
producing strains of S. platensis MA7327 and MA7339 were
confirmed to be highly resistant to PTM and PTN. No zones of
inhibition were observed around discs impregnated with high
concentrations of either molecule (Figure S3).
Expression of ptmP3 in Naive S. albus J1074 Confers
Resistance to Both PTM and PTN
We used an in vivo approach to screen whether predicted self-
resistance elements could confer resistance to PTM and/orChemistry & Biology 21, 3PTN in a sensitive Streptomyces host. Each candidate
resistance element was cloned from S. platensis MA7327
genomic DNA into the shuttle vector pBS12015 and introduced
into S. albus J1074 by conjugation (see Experimental Proce-
dures). This resulted in stable recombinant S. albus strains where
the expression vectors containing candidate resistance ele-
ments were fully integrated into the Streptomyces chromosome
(Table S2). The susceptibility of these recombinant Strepto-
myces strains to PTM and PTN was determined using the disk
diffusion assay described above, and minimum inhibitory con-
centrations (MICs; Table 1) were determined using a 96-well
plate assay format (Figure S4). S. albus harboring ptmP3
(S. albus SB12011) showed high levels of resistance to both
PTM and PTN, whereas strains harboring ptmP1, ptmP2, or
ptmP4 showed identical levels of sensitivity compared with the
naive S. albus J1074 host (Figure 2A).
Substitutions of Cys162 in PtmP3 Abolish Its Ability to
Confer Resistance
PtmP3 is homologous to the KAS I/II enzymes of FabB/F,
targets of PTM and PTN (Figure 1B). Sequence alignments
with characterized bacterial FabB/FabF enzymes confirm
that PtmP3/PtnP3 retain the three residues (Cys162, His300,
and His334) in a conserved catalytic triad (Figure S2). We
hypothesized that PtmP3/PtnP3 contribute to resistance by
carrying out the FabB/F condensation reaction inhibited by
PTM and PTN. Mutating the apparent catalytic cysteine
residue in PtmP3 would eliminate its KAS II catalytic activity
and thus its resistance to PTM and PTN. Site-directed
mutagenesis of PtmP3 gave mutants C162A, C162L, and
C162Q (see Experimental Procedures). All three substitutions
completely abolished PTM/PTN resistance and exhibited
wild-type host sensitivity (Table 1 and Figure 2B). These
results indicate that Cys162 is essential for conferring resis-
tance to PTM and PTN and support the hypothesis that
PtmP3/PtnP3 is a resistant variant of a KAS II that is competent
to constitute a functional FASII for fatty acid biosynthesis in
Streptomyces.
Deletion of a Locus Spanning ptmU4-ptmP4 Introduces
PTN Susceptibility, but Not PTM Susceptibility, in S.
platensis MA7327
To assess the essential nature of PtmP3/PtnP3 for PTM/PTN
resistance in the producing strains and explore the possibility
of additional resistance elements located within the bio-
synthetic gene cluster or elsewhere within the S. platensis
genome, a mutant strain was created in the S. platensis
MA7327 background (see Experimental Procedures). A 6.6-kb
locus containing the genes ptmU4, ptmA3, ptmP3, and
ptmP4 was deleted to yield S. platensis SB12021 mutant strain,
abolishing its ability to produce both PTM and PTN (Figures S1
and S5A). The susceptibility of SB12021 to PTM and PTN was
determined using the 96-well assay. Interestingly, the deletion
mutant is slightly more susceptible to PTN, but retains full
resistance to PTM (Table 1 and Figure S4). These data confirm
that PtmP3 is both sufficient and necessary for resistance to
PTN in the producing strains, but that an additional element
capable of providing the strain with PTM resistance, in the
absence of PtmP3, also exists.89–397, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 391
Figure 2. Disk Diffusion Assays for PTMand
PTN Susceptibility of Recombinant Strepto-
myces albus J1074 Strains that Carry Vary-
ing Expression Constructs
(A) PTM and PTN susceptibility: J1074 (wild-type),
SB12009 (J1074/pBS12016 and ptmP1 express-
ing), SB12010 (J1074/pBS12017 and ptmP2 ex-
pressing), SB12011 (J1074/pBS12018 and ptmP3
expressing), and SB12012 (J1074/pBS12019 and
ptmP4 expressing), challenged with 5, 10, 15, and
20 mg of PTM or 1.25, 2.5, 5, and 10 mg of PTN
(clockwise from top filter, respectively).
(B) PTN susceptibility: SB12011 (J1074/
pBS12018 and ptmP3 expressing); SB12015
(J1074/pBS12026 and ptmP3 [C162A] express-
ing), SB12016 (J1074/pBS12027 and ptmP3
[C162Q] expressing), and SB12017 (J1074/
pBS12028 and ptmP3 [C162L] expressing), chal-
lenged with 1.25, 2.5, 5, and 10 mg of PTN
(clockwise from top filter, respectively).
See also Figure S2 and Table S1.
Chemistry & Biology
Platensimycin and Platencin Resistance MechanismsExpression of the Native fabF from S. platensisMA7327
in a Naive Streptomyces Host Confers Resistance
to PTM
The fabF gene from the housekeeping FASII locus in S. platensis
MA7327 was a likely candidate for contributing to the PTM resis-
tance observed in the DptmU4-ptmP4 deletion mutant strain
SB12021. The S. platensis fabF was cloned, sequenced, and
utilized to construct S. albus SB12013, a recombinant S. albus
J1074 strain overexpressing the S. platensis fabF. S. albus
SB12018, a recombinant S. albus J1074 strain overexpressing
the S. albus fabF was similarly constructed as a control to rule
out potential gene dosage effect (see Experimental Procedures).
These strains were assayed for PTM/PTN susceptibility as
compared with the naive S. albus J1074 host. While S. albus
SB12018 exhibited similar susceptibility as the naive S. albus
J1074 host to both PTM and PTN, S. albus SB12013 showed
full resistance to PTM, but remained sensitive to PTN at a con-
centration of 32 mg/ml (Table 1 and Figure S3). These data
confirmed that the native fabF in PTM/PTN-producing strains
of S. platensis is inherently resistant to PTM (fully) and PTN
(partially) and is responsible for a second form of resistance
to PTM/PTN in the natural producers. However, while the
S. platensis native FabF and PtmP3 are both sufficient to confer
natural resistance levels to PTM (>256 mg/ml), PtmP3 confers
resistance to PTN at a higher level than S. platensis FabF.
Expression of the Native fabH from S. platensisMA7327
in a Naive Streptomyces Host Does Not Confer
Resistance to Either PTM or PTN
FabH from the housekeeping FASII locus in S. platensis was
similarly investigated. The S. platensis fabH gene was cloned,
sequenced, and utilized to constructS. albusSB12014, a recom-
binant S. albus J1074 strain overexpressing S. platensis fabH,
and a recombinant S. albus J1074 strain, SB12019, over-
expressing S. albus fabH was also constructed as a control
(see Experimental Procedures). These strains were assayed for
PTM/PTN susceptibility as compared with the naive S. albus
J1074 host. We observed that overexpression of fabHwas insuf-392 Chemistry & Biology 21, 389–397, March 20, 2014 ª2014 Elsevieficient to confer resistance to either PTM or PTN in the naive
host (Table 1 and Figure S4).
Either fabFor fabHwithin theHousekeeping FASII Locus
Can Be Deleted in PTM-PTN-Producing S. platensis
Strains
We sought further confirmation that the resistance element,
PtmP3, can functionally replace both FASII condensing en-
zymes, FabF and FabH, as a mechanism of resistance to their
inhibition by PTM/PTN in the producing S. platensis strains. To
delete fabF or fabH in S. platensis MA7327, a cosmid,
pBS12014, harboring the conserved Streptomyces FASII locus
(fabD-fabH-acpP-fabF) was isolated from a previously con-
structed S. platensisMA7327 genomic library (Figure S1; Sman-
ski et al., 2009). pBS12014 was modified by lRED-mediated
PCR-targeted gene replacement of fabF or fabH with an apra-
mycin resistance cassette to yield cosmids pBS12020 and
pBS12021, respectively. To ensure constitutive expression of
ptmP3, pBS12022, an integrative plasmid in which the expres-
sion of ptmP3 is under the control of the ermE* promoter, was
first introduced into S. platensis MA7327, to yield S. platensis
SB12020. Introduction of cosmids, pBS12020 or pBS12021,
into the S. platensisMA7327 wild-type or the SB12020 recombi-
nant strain by conjugation, followed by screening for double-
crossover recombinants, yielded deletion of fabF or fabH from
the chromosomal FASII locus in S. platensis (Figures S5E and
S5G). Successful isolation of DfabF and DfabH recombinant S.
platensis strains, SB12022, SB12023, SB12024, and SB12025,
respectively, demonstrated that fabF and fabH can be readily
deleted from the chromosome of PTM-PTN-producing strains.
DISCUSSION
PTM and PTN Dual Producers Have Adapted Two
Complementary Mechanisms to Confer PTM and PTN
Resistance
Acquired resistance to an antibiotic by a microorganism
generally falls into one of four major mechanisms: antibioticr Ltd All rights reserved
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pathway circumvention, or modification of the uptake and/or
efflux of the antibiotic (Wright, 2011). Target modification affects
the effectiveness of an antimicrobial agent and ultimately pro-
vides the means for developing high-level resistance to a
specific agent. Point mutations introduced into target genes,
which provide a selective advantage, are fundamental target
modifications that can confer resistance and a simple single
point mutation arising in a target gene can provide clinically
relevant resistance (Wehrli, 1983). Typically, more advanced
modification, involving several advantageous point mutations
or variation through homologous recombination with foreign
DNA, is required to alter the antibiotic-target interaction to pro-
vide high-level resistance. Other target-mediated mechanisms
of resistance include overexpression of the target gene or acqui-
sition of a replacement target gene that has a lower affinity for the
antibiotic.
Antibiotic sequestration, as in the case of bleomycin and BlmA
(Galm et al., 2005), is another possible mechanism of resistance.
The point mutations of Cys162 in PtmP3 were designed to dis-
tinguish between target replacement and antibiotic sequestra-
tion mechanisms. It has been reported that mutation of the
catalytic cysteine to glutamine in E. coli FabF resulted in a
50-fold increase in PTM binding (Wang et al., 2006). Therefore,
a sequester mechanism would introduce PTM/PTN susceptibil-
ity in the PtmP3 C162A and C162L mutants while retaining resis-
tance in the C162Q mutant. In fact, the C162A, C162L, and
C162Q mutants all lost resistance, inferring PtmP3 acts as a
target replacement, and not a sequestration protein (Figure 2B).
With our finding that S. platensis FabF is inherently resistant to
PTM and PTN, we revealed that the PTM- and PTN-producing
organisms adapted two complementary mechanisms to confer
PTM and PTN resistance: target replacement (i.e., FabF and
FabH by PtmP3/PtnP3) and target modification (i.e., FabF by a
PTM-insensitive variant).
PtmP3/PtnP3 Is the Major Self-Resistance Element,
Acting as a Functional Replacement for Both FabF and
FabH of FASII in Streptomyces
Bioinformatics analysis of the gene clusters responsible for PTM
and PTN biosynthesis revealed four candidate genes encoding
self-resistance to the producers. The results from this study
exclude PtmP1/PtnP1, PtmP2/PtnP2, and PtmP4/PtnP4 from
playing significant roles in PTM and PTN resistance, and their
functions or possible contributions to the production of PTM/
PTN remain unclear. On the other hand, we confirmed PtmP3/
PtnP3 as the major resistance element, conferring both PTM
(targeting FabF) and PTN (targeting both FabF and FabH) resis-
tance by complementing the target condensing enzymes during
inhibition. These findings are consistent with the fact that
whereas PtmP1/PtnP1, PtmP2/PtnP2, and PtmP3/PtnP3 all
show sequence similarity to KAS condensing enzymes,
PtmP1/PtnP1 and PtmP2/PtnP2 lack key active site residues
known to be essential for function. Only PtmP3/PtnP3 retains a
catalytic triad conserved among KAS I/II enzymes (Figure S2)
and was hypothesized as the best candidate for conferring
resistance in the form of an insensitive copy of the native target
of PTM or PTN. Our results confirmed this hypothesis, although
the dual capability of PtmP3/PtnP3 to provide resistance to bothChemistry & Biology 21, 3antibiotics and apparently carry out the disparate functions of
both the FabF (KAS II) and the FabH (KAS III) enzymes in Strep-
tomyces was unexpected (Figure 1B).
Evolutionary Relationship between the Two Resistance
Mechanisms Provided by PtmP3/PtnP3 and FabF in
S. platensis
Construction of the S. platensis MA7327 DptmU4-ptmP4 dele-
tion mutant strain, SB12021, revealed that upon deletion of
ptmP3, the strain becomes sensitive to PTN, but remains resis-
tant to PTM. This established the presence of another resistance
element to PTM in S. platensis. Lacking any obvious candidates
remaining within the PTM/PTN biosynthetic gene cluster
prompted investigation of the S. platensis native genes within
the housekeeping FASII locus, namely fabF, the target of PTM.
Expression of the native S. platensis fabF in a naive host
conferred high-level resistance to PTM, as well as partial resis-
tance to PTN, and implied its likely responsibility for the residual
PTM resistance observed in the SB12021 strain.
PtmP3 (ACS13710) shows high sequence homology to other
FabF enzymes, including the S. platensis MA7327 FabF
(KF543053; 51% identity and 67% similarity) and the E. coli
FabF (CAA84431; 38% identity and 55% similarity). S. platensis
MA7327 FabF shows an average of 81% sequence identity
and 90% similarity to other Streptomyces spp. FabF
enzymes, including S. coelicolor (NP_626636), S. griseus
(YP_001826617), S. avermitilis (NP_826962), and S. albus
(AGI908332), and relatively low sequence holomogy to FabF
from Escherichia coli (39% identity and 57% similarity; Fig-
ure S2). Point mutations arising in the S. platensis FabF, reducing
its affinity for PTM, may explain its resistance to PTM. However,
this essential and highly conserved primary metabolism gene
would have a very low tolerance for mutation, as illustrated by
the high sequence conservation to and among other Strepto-
myces spp FabF enzymes. Acquisition of a second fabF gene
from the environment, or more likely, duplication of its own
fabF gene near the PTM/PTN biosynthetic cluster, provides a
gene locus capable of genetic variation (without affecting pri-
mary metabolism and growth) and allows coevolution, with the
production of PTM and PTN, of a highly efficient resistance
element such as PtmP3. Furthermore, having a resistance
element such as PtmP3 residing within the PTM-PTN biosyn-
thetic cluster (as opposed to within a conserved region of the
chromosome such as the FASII locus), provides the advantage
of horizontal cluster transfer among organisms to afford other
PTM, PTN, or PTM-PTN dual producers.
Implications of PtmP3/PtnP3 as a Dual FabF and FabH
Enzyme of FASII on Fatty Acid Biosynthesis
PtmP3/PtnP3 is sufficient to confer resistance in a naive Strepto-
myces host to both PTM, an inhibitor of FabF (KAS II), and PTN, a
dual inhibitor of FabF (KAS II) and FabH (KAS III; Figure 1B).
Furthermore, isolation of viable S. platensis strains containing
DfabF or DfabH deletion in backgrounds expressing ptmP3
suggest the ability of PtmP3 to functionally complement the
activities of each of these enzymes essential for fatty acid
biosynthesis. KAS II/III are a group of enzymes that ultimately
perform the same chemical reaction (decarboxylative Claisen
condensation), but its various members are defined by their89–397, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 393
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initiates the fatty acid biosynthetic pathway by catalyzing the first
decarboxylative condensation with malonyl-ACP, while FabF
(KAS II) catalyzes the same decarboxylative condensation reac-
tion, but condenses acyl-ACP substrates of varying lengths with
malonyl-ACP to carry out the consecutive rounds of elongation
(Figure 1B).
FabH has been shown to be essential for viability in E. coli,
Streptomyces coelicolor, and Lactococcus lactis, demon-
strating FabH is the key contributor for initiating fatty acid
biosynthesis (Lai and Cronan, 2003; Li et al., 2005; Revill
et al., 2001). That PtmP3, a KAS II homolog, can apparently
replace both the functions of FabF (KAS II) and FabH (KAS III)
in Streptomyces is unexpected, but plausible. In L. lactis, a
fabH bypass mutant strain can be fully complemented by engi-
neering overproduction of the L. lactis FabF (Morgan-Kiss and
Cronan, 2008). Based on previously observed activities of E.
coli FabF/B enzymes in vitro (comparable detailed mechanistic
studies of the L. lactis enzymes in vitro have not been reported),
it has been proposed that in the absence of acyl-ACP sub-
strate, FabF decarboxylates the lone malonyl-ACP substrate
to acetyl-ACP, which becomes an available substrate for
condensation with malonyl-ACP to yield acetoacetyl-ACP, the
FabH product (Alberts et al., 1972; McGuire et al., 2000;
McGuire et al., 2001; Morgan-Kiss and Cronan, 2008). The re-
ported example in L. lactis is likely a product of the evolutionary
tendency of L. lactis toward genome minimization and meta-
bolic simplification (Makarova et al., 2006; Morgan-Kiss and
Cronan, 2008). Nonetheless, it is a significant precedent for a
bacterium evolving toward the ability to survive with only a
single functional KAS enzyme and adding complexity to the
current understanding of fatty acid synthesis in bacteria.
PtmP3/PtnP3 apparently exploits a similar evolutionary
pathway toward metabolic simplification in fatty acid biosyn-
thesis, combining the unique functions of two enzymes (each
a target) into one functional enzyme. This strategy yields a
unique enzyme for primary metabolism and provides traditional
insensitivity toward an antibiotic. Further mechanistic studies
will provide insight on how PtmP3/PtnP3 balances its apparent
expanded substrate preferences while maintaining catalytic
efficiency.
Impact of the PtmP3/PtnP3 Resistance Mechanism on
Potential Emergence of PTM and PTN Resistance in the
Clinical Setting
Bacterial fatty acid synthesis is an essential pathway, and FASII
represents an attractive target for clinically useful antibiotics.
Although the effectiveness of targeting FASII enzymes has
been debated (Balemans et al., 2010; Brinster et al., 2009,
2010; Parsons and Rock, 2011), there are examples, such as
isoniazid and triclosan, of successful FASII inhibitor use (Lu
and Tonge, 2008; Russell, 2004). The limited clinical use of anti-
biotics targeting FASII may partially account for why PTM and
PTN exhibit no cross-resistance to other key antibiotic-resistant
pathogens (Wang et al., 2006, 2007). However, the unavoidable
and highly efficient self-resistance mechanisms represent
potential sources for clinical resistance to antibiotics of natural
product origin. PtmP3/PtnP3, identified as the major natural
resistance gene to PTM and PTN in the producing organism394 Chemistry & Biology 21, 389–397, March 20, 2014 ª2014 ElsevieS. platensis, is a potential source of clinical resistance. Its identity
as an apparent ‘‘hybrid’’ KAS II/III isoform capable of comple-
menting both native FabF (KAS II) and FabH (KAS III) enzymes
in Streptomyces represents a clever resistance mechanism
developed by a producer to counteract an inhibitor (PTN) of
two separate essential targets. The potential for PtmP3/PtnP3
to confer resistance to other clinically relevant FabF/FabH inhib-
itors as well as its ability to complement FabF/FabH and/or
confer resistance in other organisms and pathogens should be
investigated further. These studies will guide the future develop-
ment of new and effective therapeutics targeting FASII.SIGNIFICANCE
PTM and PTN are potent inhibitors of bacterial fatty
acid synthesis—PTM specifically inhibits the elongation
condensing enzymes FabB/F, and PTN dually inhibits FabF
and the initiation condensing enzyme FabH. PTM and PTN
have emerged as promising antibacterial drug leads. We
previously characterized the PTM and PTN biosynthetic
machineries in the PTM-PTN dual producer S. platensis
MA7327 and the PTN producer S. platensisMA7339, respec-
tively. We now identify two mechanisms for PTM and PTN
resistance in the producers. The ptmP3 or ptnP3 genewithin
the PTM-PTN or PTN biosynthetic cluster was identified as
the major resistance-conferring element. Expression of
ptmP3 in a naive Streptomyces host conferred full
resistance to both PTM and PTN, whereas site-directed
mutagenesis of the active site Cys162 of PtmP3 completely
abolished its ability to confer resistance. The fabF gene
within the housekeeping fatty acid synthase locus was iden-
tified as the second resistance-conferring element. Deletion
of ptmP3 alone was insufficient to eliminate PTM resistance
from the producer, and expression of S. platensis fabF in a
naive Streptomyces host conferred full resistance to PTM.
PtmP3 and FabF in the PTM and PTN producers therefore
confer PTM and PTN resistance by target replacement (i.e.,
FabF and FabH by PtmP3) and target modification (i.e.,
FabF by a PTM-insensitive variant), respectively. PtmP3
also represents an unprecedented mechanism for fatty
acid biosynthesis in which FabH and FabF are functionally
replaced by a single condensing enzyme. These findings
challenge the current paradigm for fatty acid biosynthesis
and should be considered in future development of effective
therapeutics targeting fatty acid synthase.EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, Primers, and Culture Conditions
For a complete list of bacterial strains, plasmids, and PCR primers used in this
study, see Tables S2 and S3. E. coli DH5a was used for routine cloning
(Sambrook and Russel, 2001). Vectors pGEM-T Easy (Promega) and
pCR2.1-TOPO (Invitrogen) were obtained from commercial sources. PTM
and PTN producers, S. platensis MA7327 and S. platensis MA7339, respec-
tively, were kindly provided by Dr. Sheo B. Singh at Merck Research Labora-
tories. E. coli-carrying plasmids were grown in Luria-Bertani (LB) medium and
selected using appropriate antibiotics (Sambrook and Russel, 2001). Standard
media and protocols were used for Streptomyces growth and sporulation
(Kieser et al., 2000). Media components and all other chemicals were obtained
from standard commercial sources.r Ltd All rights reserved
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Plasmid preparation from E. coli and gel extraction was carried out with com-
mercial kits (QIAGEN and Omega Bio-Tek). Total StreptomycesDNA isolation,
restriction endonuclease digestions, and ligations were performed according
to standard procedures (Kieser et al., 2000; Sambrook and Russel, 2001).
Automated DNA sequencing was performed at the University of Wisconsin
Biotechnology Center (Madison, WI) or by GENEWIZ, and oligonucleotide
primer synthesis was completed by Integrated DNA Technologies.
PTM and PTN
The PTM and PTN utilized in this study was isolated and purified from fermen-
tations of S. platensis SB12002 and S. platensis SB12001, respectively, as
previously described (Smanski et al., 2009).
Disk Diffusion Assay
A standard disk diffusion assay was used to determine susceptibility of wild-
type and recombinant Streptomyces strains to PTM and PTN. In brief, quanti-
ties of PTM (5–200 mg) or PTN (1.25–40 mg) in methanol were applied to 7 mm
paper disks (Whatman) and dried. The disks were placed onto solid R2YE agar
plates applied with dense Streptomyces liquid culture (48 hr). These plates
were incubated overnight at 30C and the zones of inhibition were subse-
quently observed.
Plate Assay for Measuring the MIC Values
Molten R2YE agar was prepared and contained either 0, 0.25, 0.5, 1, 2, 4, 8, 16,
32, 64, 128, or 256 mg/ml of PTM, or 0, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16,
32, or 64 mg/ml of PTN. These mixtures were applied to sterile 96-well plates;
each well contained 100 ml of agar media. Each well was inoculated with 10 ml
of sterile water containing 103 Streptomyces spores. Plates were incubated
overnight at 30C. Growth in wells containing PTM or PTN was compared with
control wells (no antibiotics added).
Cloning and Constructing the Expression Plasmids of the Putative
Resistance Elements
Putative resistance elements ptmP1, ptmP2, ptmP3, and ptmP4 were ampli-
fied from S. platensis MA7327 genomic DNA using LA Taq with GC Buffer II
(Clontech Laboratories) according to the manufacturer’s instructions. The re-
sulting PCR products were cloned into pGEM-T Easy or pCR2.1-TOPO. These
constructs were used for subcloning individual elements into pBS12015, a
modifiedStreptomyces integrating vector containing the apramycin resistance
cassette and the constitutively active promoter, ermE*, upstream of the multi-
ple cloning site to ensure a high level of expression of the insert (Bierman et al.,
1992). The expression plasmids pBS12016, pBS12017, pBS12018, and
pBS12019 (containing ptmP1, ptmP2, ptmP3, and ptmP4, respectively)
were constructed for expression of individual elements in S. albus J1074.
Site-Directed Mutagenesis of ptmP3
Point mutations in ptmP3 were generated through site-directed mutagenesis
by overlap extension using PCR (Ho et al., 1989). The mutagenized fragments
were cloned into pGEM-T Easy vector and subcloned into pBS12015 to yield
pBS12026 (C162A), pBS12027 (C162Q), and pBS12028 (C162L).
Construction and Isolation of Recombinant Streptomyces Strains
After transformation of each pSET152ermE*-derived expression construct
(Table S2) into E. coli ET12567/pUZ8002 electrocompetent cells, intergeneric
conjugation between E. coli and Streptomyces was performed according to
standard protocol (Kieser et al., 2000). This resulted in stable, recombinant
strains of Streptomyceswith the various expression constructs fully integrated
into the Streptomyces chromosome. For a complete list of recombinant
strains, see Table S2.
Construction of the DptmU4-ptmP4 Mutant S. platensis SB12021
Cosmid pBS12005 was modified by PCR targeting, using standard protocols
(Gust et al., 2003), to generate the construct, pBS12023. Briefly, primers
RLDC2for and RLDC2rev were used to amplify the aac(3)IV cassette from
pIJ773. Introduction of the amplified fragment into E. coli BW25113/pIJ790/
pBS12005 resulted in the replacement of the locus spanning ptmU4-ptmP4
with the apramycin resistance cassette on pBS12005 to generateChemistry & Biology 21, 3pBS12023. The construct was introduced into S. platensis MA7327 by inter-
generic conjugation using E. coli ET12567/pUZ8002 as the donor strain. Apra-
mycin-resistant exconjugants were picked and replica-plated to identify
apramycin-resistant, kanamycin-sensitive clones in which homologous
recombination on each side of the locus of gene replacement had taken place,
resulting in S. platensis SB12021. Double crossover mutants were verified by
PCR and Southern analysis (Figures S5B and S5D).
Cloning and Sequencing the fabF and fabH Genes within the FASII
Locus from S. platensis MA7327 and S. albus J1074
Sequence data for the native fab genes in S. platensis MA7327 and MA7339
strains were unavailable. Genome sequences of other Streptomyces spp.
were analyzed for the homologous fab cluster containing fabD, fabH, acpP,
and fabF. Primers for fabF amplification were designed based on highly
conserved regions found in S. coelicolor, S. avermitilis, and S. griseus (Table
S3). Fragments containing the fabF or fabH genes were amplified from
S. platensisMA7327 and S. platensisMA7339 genomic DNA. These fragments
were cloned into pGEM-T Easy for sequencing and further subcloned into the
Streptomyces integrating vector, pBS12015, to yield pBS12020 and
pBS12021. Similar procedures were followed for the construction of
pBS12029 and pBS12030, the integrating vector pBS12015 containing
S. albus fabF and fabH, respectively.
Construction of the fabF or fabH Deletion Mutants S. platensis
SB12022 and SB12023
Cosmids containing the S. platensis fab cluster were isolated from a previously
constructedS. platensisMA7327 genomic library (Smanski et al., 2009). A 10 ml
culture containing the genomic library was diluted to 106 cells/ml and spread
onto LB plates containing 50 mg/ml of kanamycin. PCR primers FabHscreen-
For and FabHscreenRev were used to screen resulting single colonies.
Colonies yielding the expected 432 bp band were isolated and their respective
cosmids purified using standard methods. Cosmid pBS12014, isolated from
the S. platensis MA7327 cosmid library and verified to contain both fabF and
fabH, was transformed into E. coli BW25113/pIJ790 to generate DfabF and
DfabH single knockout mutants using the lRED-mediated PCR-targeting
mutagenesis method (Gust et al., 2003). The modified cosmids were intro-
duced to S. platensis MA7327 by intergeneric conjugation using E. coli
ET12567/pUZ8002 as the donor strain. Apramycin-resistant exconjugants
were selected and these putative single-crossover recombinants were replica
plated to identify apramycin-resistant, kanamycin-sensitive clones in which
homologous recombination on each side of the locus of gene replacement
had taken place. Single and double crossover mutants were verified by PCR
and Southern analysis. Strains S. platensis SB12022 and SB12024 were
confirmed to be DfabF::aac(3)IV mutants, while S. platensis SB12023 and
SB12025 were confirmed to be DfabH::aac(3)IV mutants. For Southern
analysis, digoxigenin labeling of DNA probes, hybridization, and detection
were performed according to themanufacturer’s protocols for DIG-High Prime
(Roche Diagnostics).
ACCESSION NUMBERS
The GenBank accession numbers for the S. platensis MA7327 fabF and fabH
genes are KF543053 and KF543054, respectively.
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